ELTP News Alert Elite Pharma Inc (ELTP) 0.2040 01/06/2015 17

New Post Public Reply Private Reply Replies (0) Message Board

Jan 6, 2015 at 6:36 PM

Elite Pharma Inc (ELTP) 0.2040 $ELTP

Elite Pharmaceuticals receives second abuse deterrent drug formulation patent in Canada
M2 - Wed Dec 17, 8:09AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) announced on Tuesday that it has received the second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" to expand the scope and reach of its patent estate internationally.

Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
GlobeNewswire - Tue Dec 16, 7:38AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property protection covering the Company's abuse deterrent technology with the issuance of a second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance continues to expand the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
GlobeNewswire - Wed Dec 03, 8:56AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for ELI-201, Elite's twice daily abuse-deterrent oxycodone product which utilizes Elite's proprietary pharmacological abuse-deterrent technology.

Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 19, 4:49PM CST

Elite Pharmaceuticals achieves 8% increase in revenues for Q2 fiscal 2015
M2 - Wed Nov 19, 6:15AM CST
Specialist pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Tuesday that its consolidated revenues was USD1.3m for the second quarter of fiscal year 2015 ended 30 September 2014.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Tue Nov 18, 5:24PM CST
Revenues increase by 8%

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
GlobeNewswire - Thu Nov 13, 4:02PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that management will host a conference call to provide a quarterly business update on Wednesday, November 19, 2014 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Fri Oct 24, 6:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., M.B.A., as Vice President of Legal, Dr. Jason LePree as Vice President of Scientific Affairs and Dr. Sophy Abraham as Head of Regulatory Affairs.

Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
GlobeNewswire - Tue Sep 09, 6:04AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain.

Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 12:47PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with niche generic products, today announced that Nasrat Hakim, Elite's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Healthcare Conference on Tuesday, September 9, 2014 at 2:55 PM Eastern Time. The conference is being held at The New York Palace Hotel in New York City.

OTC Daily Trading News: Evoq Properties, Inc. MedBox, Inc. LabStyle Innovations Corp, MyEcheck, Inc. Elite Pharmaceuticals, Inc.
PR Newswire Europe - Tue Aug 19, 10:11AM CDT
LONDON, August 19, 2014 /PRNewswire/ --

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
GlobeNewswire - Thu Aug 14, 3:14PM CDT
Revenues Increase by 61%, Product Development on Schedule

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014
GlobeNewswire - Wed Aug 13, 6:09AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide a quarterly business update at 11:00 AM ET on Monday, August 18, 2014. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals reports launch of pivotal bioequivalence study of ELI-201 in healthy volunteers to address issues in prescription drug abuse
M2 - Wed Jul 16, 9:08AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) disclosed on Tuesday the dosing of the first volunteer in a pivotal bioequivalence study of ELI-201 utilising its proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
GlobeNewswire - Tue Jul 15, 10:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-201, the Company's twice daily abuse deterrent oxycodone/naltrexone product, utilizing Elite's proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals posts higher consolidated revenues of USD4.6m for fiscal 2014
M2 - Tue Jul 01, 2:53AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTC BB:ELTP) stated on Monday its consolidated revenues of USD4.6m for the fiscal year ended 31 March 2014 (fiscal 2014).

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
GlobeNewswire - Mon Jun 30, 1:05PM CDT
Revenues Increase by 35%, Product Development Accelerating

Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014
GlobeNewswire - Thu Jun 26, 9:56AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ortho Molecular and HANS: Streamlining Functional Medicine

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

CURE Intl and Thoughtworks Step Into Digital Era

Pushing Paper Out, Digitizing In In a world where tech is king, why were hospitals—crucial, life-saving institutions—still bogged down by dusty folders and ink smudges? Well, not anymore for CURE International, not with Thoughtworks stepping up to the plate. This ain't just swapping paper for pixels; it's a lifeline for kids getting world-class surgical care without...

Jinko Solar Joins B20 Summit: Energy Forefront Focus

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Agilyx's Q3 Update: GreenDot Shines Amid Mixed Results

Peeking into Agilyx's Financial Odyssey Just as I sip my morning coffee pondering the highs and lows of the market, here comes Agilyx ASA splashing some liquidity on the scene. The Q3 report paints the company in various shades—from solid greens to hesitant reds. Nothing like the thrill of untangling mixed results over a quiet day, huh? GreenDot's Climb to Profitability...

Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

LG Innotek Scores Hat Trick with CES Innovation Wins

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

RF MEDICAL Expands into Europe with New CE Certification

RF MEDICAL Secures CE Marking for Mi-BLATOR™ Just when you think the European medical device market's hit its saturation point, RF MEDICAL decides to kick the door open with their Mi-BLATOR™ microwave ablation system. This ain't just another plastic gadget, folks; it's got that shiny new CE marking under the European Union's Medical Device Regulation (MDR). Now, what...

BD Sets Stage for Investor Day in December 2026

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...